TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23958023
Drug: Microalgae (MA)
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microalgae (MA) supplement (200 g/d)
Study: 23958023
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no marine oil supplement)
Study: 19116800
Drug: Insomnia treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insomnia treatment study volunteers (n = 120)
Study: 19116800
Drug: Clinical patients
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical patients seeking treatment (n = 106)
Study: 17263835
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg once-daily (n = 122)
Study: 17263835
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice-daily plus phenethicillin 250 mg four-times-daily (n = 120)
Study: 8500785
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg metoclopramide
Study: 8500785
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg metoclopramide
Study: 8500785
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg metoclopramide
Study: 7481852
Drug: Combination regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimens
Study: 2553879
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with MVP
Study: 31550354
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) trivalent inactivated vaccine
Study: 31550354
Drug: Standard-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (SD) trivalent inactivated vaccine
Study: 23126307
Drug: Aspirin initiated
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin initiated before 16 weeks of gestation (from meta-analysis)
Study: 19427269
Drug: High-dose ascorbic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ascorbic acid (about 30 mg/kg/day)
Study: 15541413
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of Gynol II gel
Study: 15541413
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of Gynol II gel
Study: 11185653
Drug: Alcohol consumption
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol consumption (mean 81.8 g/d, range 40-150 g/d)
Study: 9293612
Drug: Valaciclovir (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir (1000 mg, twice daily)
Study: 9293612
Drug: Acyclovir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (200 mg, 5 times daily)
Study: 28478107
Drug: Individualized endobronchial
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized endobronchial photodynamic therapy (PDT) under fluorescence control, violet light 408nm, diagnostic light.
Study: 26541878
Drug: Loperamide-simeticone chewable
Normalized name: loperamide / simethicone Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide-simeticone chewable tablet
Study: 20928835
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc gluconate plus corticosteroid treatment
Study: 18602474
Drug: MK (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK (1.0 mg morphine + 5 mg ketamine/bolus)
Study: 18602474
Drug: MO (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MO (1.5 mg morphine/bolus)
Study: 17140533
Drug: Carisolv group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carisolv group (excavation with a chemical solution and special blunt hand instruments)
Study: 17140533
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of residual caries and cervical gaps
Study: 14523778
Drug: Indinavir-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir-based therapy (with or without other antiretroviral drugs)
Study: 10921143
Drug: Tong Luo
Normalized name: CAMPHOR (NATURAL) 5 g / MENTHOL 3.4 g TRANSDERMAL POULTICE [TONG LUO QU TONG GAO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tong Luo Kai Bi Tablets
Study: 10921143
Drug: Rheumatic Semen
Normalized name: Hippocastani semen
DrugBank: Horse chestnut (DB13195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheumatic Semen Strychni Tablets
Study: 1665177
Drug: Lisinopril-hydrochlorothiazide 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril-hydrochlorothiazide 20 mg and 12.5 mg (L/HCTZ)
Study: 1665177
Drug: Lisinopril 40
Normalized name: lisinopril 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 40 mg once daily (L40)
Study: 26682721
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone 8 mg
Study: 29773484
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 8 mg
Study: 26682721
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline 0.9%
Study: 21905001
Drug: Ocrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab 200 mg
Study: 21905001
Drug: Ocrelizumab 500
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab 500 mg
Study: 20390409
Drug: Intramuscular clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular clodronate at a dose of 100 mg weekly for 12 months
Study: 12418424
Drug: Nitrates administered
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrates administered orally and/or transdermally
Study: 9659191
Drug: alpha tocopherol
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha tocopherol (vitamin E) 50 mg/day
Study: 9659191
Drug: alpha tocopherol
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha tocopherol (vitamin E) 50 mg/day and beta carotene 20 mg/day
Study: 9659191
Drug: beta carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta carotene 20 mg/day
Study: 8618789
Drug: Indomethacin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (3 x 0.2 mg/kg/12 h)
Study: 8618789
Drug: Aspirin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (4 x 15 mg/kg/6 h)
Study: 2744182
Drug: Sequential embryo
Normalized name: human embryo tissue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential embryo transfer at 44 to 48 and 68 to 72 hours after insemination
Study: 30242736
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate (200 mg once daily for 6 days)
Study: 23403680
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg every 12 hours for 10 days)
Study: 20131551
Drug: Topical diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diltiazem hydrochloride ointment (2%)
Study: 20131551
Drug: Topical glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glyceryl trinitrate ointment (0.2%)
Study: 15651756
Drug: Twice-daily indinavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily indinavir/ritonavir (800/100 mg) regimen
Study: 15651756
Drug: Three-times-daily indinavir
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-times-daily indinavir regimen
Study: 10808389
Drug: Atenolol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (25 mg)
Study: 8582096
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (SV) 400 mg
Study: 3029790
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (SV) 800 mg
Study: 12665
Drug: High-dose lorazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lorazepam
Study: 12665
Drug: Low-dose lorazepam
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lorazepam
Study: 30785704
Drug: Buccal graft
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal graft
Study: 18767579
Drug: Cranial needling
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial needling plus medication
Study: 10233187
Drug: Tinidazole 500
Normalized name: tinidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 500 mg (OCT)
Study: 10233187
Drug: Metronidazole 400
Normalized name: metronidazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 400 mg (OCM)
Study: 7759660
Drug: Metyrapone and
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metyrapone and hydrocortisone (30 mg daily hydrocortisone)
Study: 25683704
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol esters (4 g)
Study: 21748500
Drug: Prophylactic hypervolemic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic hypervolemic therapy
Study: 21748500
Drug: Hyperdynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperdynamic therapy
Study: 19522983
Drug: High-dose squalene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose squalene (27 g/day)
Study: 19522983
Drug: Low-dose squalene
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose squalene (13.5 g/day)
Study: 19522983
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of squalene
Study: 11710709
Drug: Ginger extract
Normalized name: ginger extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger extract (EV.EXT 77), administered twice daily for 6 weeks
Study: 10150223
Drug: Pre-hospital beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hospital beta-blocker treatment (intravenous injection of atenolol)
Study: 10150223
Drug: Pre-hospital placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hospital placebo treatment
Study: 12791627
Drug: 240 mL
Normalized name: Iron 5 MG/240 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mL orange juice fortified with 1000 IU vitamin D(3) daily for 12 weeks
Study: 10815856
Drug: Flashlamp‐pumped pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flashlamp‐pumped pulsed dye laser (FPDL) therapy for superficial hemangiomas
Study: 10815856
Drug: Flashlamp‐pumped pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flashlamp‐pumped pulsed dye laser (FPDL) therapy for mixed hemangiomas
Study: 10815856
Drug: Flashlamp‐pumped pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flashlamp‐pumped pulsed dye laser (FPDL) therapy for superficial hemangiomas in involution phase
Study: 8970899
Drug: 1.2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g/day of oral calcium as carbonate
Study: 26780938
Drug: Immediate discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate discontinuation group (IDG)
Study: 24650219
Drug: Daily 20
Normalized name: Culturelle Probiotics Digestive Daily 200mg-10 Billion CFU Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 20 g lipid-based multi-micronutrient (MMN) supplement; additional 300 kcal/d for women with BMI <20 or low gestational weight gain
Study: 22436129
Drug: Allopurinol 200/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 200/300 mg
Study: 17495810
Drug: Calcium hydroxyapatite
Normalized name: Calcium hydroxyapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxyapatite preparations
Study: 14962813
Drug: raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: raloxifene (60 or 120 mg/day)
Study: 11591882
Drug: Glycerol ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol ingestion (1 g glycerol in 20 ml H2O x kg(‐1) body weight)
Study: 11591882
Drug: Control (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (20 ml H2O x kg(‐1) body weight)
Study: 2928998
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol (400, 600, and 800 micrograms)
Study: 2928998
Drug: Inhaled isoprenaline
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled isoprenaline (400, 600, and 800 micrograms)
Study: 2928998
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (400, 600, and 800 micrograms)
Study: 26316325
Drug: Epratuzumab (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epratuzumab (1,200 mg infusions at weeks 0 and 2 of repeating 12-week cycles) plus standard of care
Study: 17373638
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg qd
Study: 25867771
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin qd
Study: 23673304
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (COMBO)
Study: 20608826
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of depression in patients with heart disease; specific intervention details not available.
Study: 20608826
Drug: Recognition and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recognition and treatment of depression; specific intervention details not available.
Study: 10521635
Drug: Lateral glide
Normalized name: Chamois Glide
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lateral glide treatment technique
Study: 1679870
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin and aerosol inhalations of colistin twice daily for 3 weeks
Study: 1679870
Drug: No anti-pseudomonas
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-pseudomonas chemotherapy
Study: 22559269
Drug: Prophylactic intra-graft
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intra-graft administration of abciximab and verapamil followed by direct stenting (n=91)
Study: 19280232
Drug: Bone substitutes
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone substitutes (allografts, ceramics, demineralized bone matrix, osteoinductive factors, autogenous platelet concentrate, mesenchymal stem cells, gene therapy)
Study: 12556375
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg ciprofloxacin (one dose)
Study: 12556375
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg ciprofloxacin (two doses every 12 hours)
Study: 10997367
Drug: Thickened formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thickened formula (0.4 g galactomannan per 100 ml diluted milk)
Study: 1950094
Drug: Trivalent split
Normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent split influenza vaccine
Study: 1950094
Drug: Trivalent subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent subunit influenza vaccine
Study: 15280979
Drug: Intravenous hyoscine
Normalized name: HYOSCINE HYDROBROMIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hyoscine
Study: 28092404
Drug: Myoinositol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myoinositol (1000 mg twice a day)
Study: 25638326
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus bevacizumab (15 mg/kg intravenously on day 1 or 2)
Study: 17306016
Drug: Bolus hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bolus hydrocortisone (200 mg/day)
Study: 17306016
Drug: Continuous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Continuous hydrocortisone infusion (200 mg/day)
Study: 10381298
Drug: Fluvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin treatment for 52 weeks
Study: 8730228
Drug: Diazepam (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (four logarithmically increasing doses)
Study: 8730228
Drug: Placebo (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (four logarithmically increasing doses)
Study: 1888825
Drug: ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine (300 mg nocte)
Study: 1888825
Drug: cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine (800 mg nocte)
Study: 1888825
Drug: famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine (40 mg nocte)
Study: 6337578
Drug: Imipramine hydrochloride
Normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine hydrochloride with behavior therapy (BT)
Study: 6337578
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with behavior therapy (BT)
Study: 30591285
Drug: Immunosuppressants
Normalized name: IMMUNOSUPPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressants
Study: 30247524
Drug: Bevacizumab (B)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (B) added to chemotherapy (capecitabine (C)±mitomycin (M))
Study: 30247524
Drug: Bevacizumab (B)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (B) added to first-line capecitabine-based chemotherapy
Study: 17915999
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus 3 days of AZM, 500 mg
Study: 12114037
Drug: Antioxidant vitamin
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamin supplementation (600 mg vitamin E, 250 mg vitamin C, and 20 mg beta‐carotene daily)
Study: 9579771
Drug: Irbesartan 75
Normalized name: irbesartan 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 75 mg
Study: 10193713
Drug: Irbesartan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (all doses)
Study: 10193713
Drug: Irbesartan (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (75 mg and 150 mg)
Study: 7474602
Drug: Bilateral orchiectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral orchiectomy and 25 mg/day of etoposide every 2 weeks for 6 months
Study: 7474602
Drug: Bilateral orchiectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral orchiectomy and 560 mg/day of estramustine phosphate for 6 months
Study: 7860471
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg once daily
Study: 108152
Drug: Phyllocontin tablets
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllocontin tablets (12.5 mg/kg)
Study: 108152
Drug: Phyllocontin tablets
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllocontin tablets (12.5 mg/kg twice daily)
Study: 17853036
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg intravenously 60 min before the procedure
Study: 17853036
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg intravenously 60 min before the procedure
Study: 16027246
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (DC) 100 g per day (containing 88 mg flavanols)
Study: 16027246
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (DC) 100 g per day
Study: 16027246
Drug: Flavanol-free white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavanol-free white chocolate (WC) 90 g per day
Study: 10643800
Drug: Caffeine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (100 mg) and placebo beverage
Study: 10643800
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill and alcohol (0.55 g/kg in 10% (v/v) solution)
Study: 10643800
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill and placebo beverage
Study: 8865536
Drug: Protein C,
Normalized name: protein C, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein C, Antithrombin III, Heparin-Cofactor II, and plasminogen levels
Study: 8865536
Drug: Pill use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill use
Study: 6528679
Drug: Citrate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate infusion
Study: 29652271
Drug: Levosimendan (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.1 μg/kg/min) administered preoperatively for 24 hours including intraoperative period
Study: 24894735
Drug: Mindfulness-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based intervention (3 × 1 h weekly sessions)
Study: 24894735
Drug: Dissonance-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dissonance-based intervention (3 × 1 h weekly sessions)
Study: 22728005
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention with optimal medical therapy
Study: 16009170
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate instillation (300 mL)